-
Achieved 36% annual revenue growth driven by disciplined execution and the predictable, recurring nature of the point-of-care EEG business model.
-
Expanded the total addressable market from $2 billion to $3.5 billion by securing regulatory clearances for neonatal seizure detection and delirium monitoring.
-
Increased commercial infrastructure to 55 territories, creating a strong backlog of accounts expected to accelerate acquisition rates in 2026 and 2027.
-
Leveraged FedRAMP High authorization to unlock the 170-hospital VA system, transitioning from a successful pilot to active system-wide expansion.
-
Maintained high gross margins of 88% for the full year through manufacturing efficiencies and a strategic transition to a Vietnam-based production line.
-
Positioned the platform to address the ‘acute brain failure’ of delirium, targeting a $1 billion greenfield market where no other FDA-cleared monitoring device exists.
-
Full-year 2026 revenue guidance of $111 million to $115 million assumes a conservative ramp for new products and continued core seizure market penetration.
-
Anticipates a full commercial launch of neonatal and pediatric products in Q2 2026, with meaningful revenue contributions expected to ramp as the company moves from the pilot stage to full market availability.
-
Plans to initiate a delirium commercial pilot in Q2 2026 to optimize workflows and build clinical evidence ahead of a full launch in late 2026 or 2027.
-
Expects to maintain gross margins in the mid-80% range throughout 2026 by mitigating tariff impacts through the established Vietnam manufacturing facility.
-
Focusing 2026 R&D efforts on clinical data generation for LVO stroke detection following the receipt of FDA Breakthrough Device designation.
-
Identified a temporary increase in G&A expenses for the first half of 2026 due to concentrated legal costs related to the ITC patent litigation against Natus.
-
Noted that neonatal patients are eligible for high-value DRG payments, which is expected to drive hospital administrative interest and adoption momentum.
-
Acknowledged that while the platform allows for remote software updates, expanding into new hospital departments still requires a multi-month sales and training cycle.
-
Confirmed a commitment to achieving cash flow breakeven with existing cash on hand, prioritizing ROI-driven investments in R&D and sales.
-
Management maintains a conservative guidance philosophy to ensure delivery on stated numbers, noting that new market opportunities will primarily impact 2027.
-
The pipeline for neonatal and delirium products is expected to start contributing toward the end of 2026 after multi-month sales and contracting cycles.
